BioXcell热销产品–InVivoPlus anti-mouse PD-1 (CD279)

发表于由

BioXcell热销产品–InVivoPlus anti-mouse PD-1 (CD279)

BioXcell热销产品–InVivoPlus anti-mouse PD-1 (CD279)

 

产品描述：

BioXcell InVivoPlus anti-mouse PD-1 RMP1-14单克隆抗体与小鼠PD-1（也称为CD279）反应。PD-1是一种50-55kDa的细胞表面受体，由Pdcd1基因编码，属于Ig超家族的CD28家族。PD-1在CD4和CD8胸腺细胞以及活化的T和B淋巴细胞和髓细胞上瞬时表达，在成功消除抗原后PD-1的表达下降。此外，在B细胞前阶段，Pdcd1 mRNA在发育中的B淋巴细胞中表达。PD-1的结构包括ITIM（基于免疫受体酪氨酸的抑制基序），这表明PD-1负调控TCR信号。PD-1通过结合B7家族的成员PD-L1和PD-L2发出信号。在配体结合后，PD-1信号传导抑制T细胞活化，导致增殖减少，细胞因子产生和T细胞死亡。此外，PD-1敲除动物表现出扩张型心肌病、脾肿大和外周耐受丧失，在小鼠的外周耐受性和预防自身免疫性疾病中发挥关键作用。诱导的PD-L1表达常见于许多肿瘤，包括鳞状细胞癌、结肠癌和乳腺癌。PD-L1过度表达会导致肿瘤细胞对CD8T细胞介导的裂解的抗性增加。在黑素瘤的小鼠模型中，可以通过用阻断PD-L1与其受体PD-1之间相互作用的抗体治疗来暂时抑制肿瘤生长。由于这些原因，目前正在探索抗PD-1介导的免疫疗法作为癌症治疗。与J43抗体一样，RMP1-14抗体已显示阻断小鼠PD-L1-Ig和小鼠PD-L2-Ig与PD-1的结合。


BioXcell热销产品--InVivoPlus anti-mouse PD-1 (CD279)

产品详情：

产品名称

InVivoPlus anti-mouse PD-1 (CD279)

产品货号

BP0146

产品规格

5/25/50/100mg

反应种属

Mouse

克隆号

RMP1-14

同种型

Rat IgG2a, κ

免疫原

Syrian Hamster BKH cells transfected with mouse PD-1 cDNA

实验应用

in vivo blocking of PD-1/PD-L signaling

产品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

纯度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

无菌处理

0.2 µm filtration

纯化方式

Protein G

RRID

AB_10949053

分子量

150 kDa

小鼠病原检测

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存条件

抗体原液保存在4°C，不能冷冻保存。

推荐同型对照

InVivoPlus rat IgG2a isotype control, anti-trinitrophenol（货号BP0089）

推荐抗体稀释液

InVivoPure pH 7.0 Dilution Buffer（货号IP0070）

 

为什么选择InVivoPlus抗体？

InVivoPlus级别的产品内毒素含量更低，经过多种实验验证，更适合用于体内实验研究

 

BioXcell热销产品--InVivoPlus anti-mouse PD-1 (CD279) 

 

该产品自上市已被多篇SCI文献引用，品质有保证，以下是部分已发表的文献引用：


应用

文章

体内PD-1/PD-L信号阻断

(in vivo blocking of PD-1/PD-L signaling)

1. Triplett, T. A., et al. (2018). ‘Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme’ Nat Biotechnol 36(8): 758-764.

2. Grasselly, C., et al. (2018). ‘The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent’ Front Immunol 9: 2100.

3. Moynihan, K. D., et al. (2016). ‘Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses’ Nat Med. doi : 10.1038/nm.4200.

4. Ngiow, S. F., et al. (2015). ‘A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1’ Cancer Res 75(18): 3800-3811.

5. Evans, E. E., et al. (2015). ‘Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies’ Cancer Immunol Res 3(6): 689-701.

6. Zelenay, S., et al. (2015). ‘Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity’ Cell 162(6): 1257-1270.

7. Zander, R. A., et al. (2015). ‘PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity’ Cell Host Microbe 17(5): 628-641.

 


更多产品详情请咨询 BioXcell 中国代理——上海金畔生物